Joe Y. Chang/X
May 21, 2025, 18:49
Joe Y. Chang on upcoming PTCOG 63: IMRT vs IMPT Phase III trials
Joe Y Chang, Professor, Clinical Section Chief at MD Anderson Cancer Center, shared a post on X:
“Join us at PTCOG 63 to explore cutting-edge particle therapy and novel Phase III randomized studies comparing IMRT and IMPT.
With advancements in LET optimization, immune modulation, we are moving PT into the new era.”
More posts featuring Joe Y Chang on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 7, 2025, 17:41
Jun 7, 2025, 16:47
Jun 7, 2025, 16:40
Jun 7, 2025, 16:30
Jun 7, 2025, 16:07
Jun 7, 2025, 15:49